Consistent responses to immunotherapy have been reported in patients with the most common type of colorectal tumors, known as MSS mCRC, with 61% of patients seeing their tumor shrink or remain stable after receiving treatment.
Co-authored by Professor Justin Stebbing of Anglia Ruskin University , who describes the results as"potentially game changing," the study focused on the most common type of colorectal tumours, known as MSS mCRC, or microsatellite stable metastatic colorectal cancer. Of the patients in the phase 1 trial, 101 took part in a six-month follow-up and of these, 61% of them saw their tumour shrink or remain stable after receiving a combination of botensilimab and balstilimab . The most common side-effects, or treatment-related adverse events, were diarrhea and fatigue.
Joint first author Dr Andrea Bullock, Assistant Professor in Medicine at Beth Israel Deaconess Medical Center, said:"This study sheds light on the potential of the BOT/BAL combination to treat microsatellite stable metastatic colorectal cancer, the most common form of colorectal cancer which has historically not responded to immunotherapy, and we hope our results will offer new hope for those diagnosed.
Source: Healthcare Press (healthcarepress.net)
Breast Cancer Lung Cancer Cancer Pancreatic Cancer Skin Cancer Leukemia Ovarian Cancer
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: wsyx6 - 🏆 444. / 53 Read more »
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: WGAL - 🏆 331. / 59 Read more »
Source: cnnbrk - 🏆 393. / 55 Read more »
Source: fox5ny - 🏆 587. / 51 Read more »
Source: CNBC - 🏆 12. / 72 Read more »